Literature DB >> 8851513

Inhibition of cortical spreading depression by L-701,324, a novel antagonist at the glycine site of the N-methyl-D-aspartate receptor complex.

T P Obrenovitch1, E Zilkha.   

Abstract

1. Spreading depression (SD) is a propagating transient suppression of electrical activity, associated with cellular depolarization, which probably underlies the migraine aura and may contribute to neuronal damage in focal ischaemia. The purpose of this study was to examine whether L-701,324 (7-chloro-4-hydroxy-3-(3-phenoxy)phenyl-2-(1H)-quinolone), a high affinity antagonist at the glycine site of the N-methyl-D-aspartate (NMDA) receptor complex, inhibits the initiation and propagation of K(+)-induced SD in the rat cerebral cortex in vivo. 2. Microdialysis probes incorporating a recording electrode were implanted in the cerebral cortex of anaesthetized rats and perfused with artificial cerebrospinal fluid (ACSF). Five episodes of repetitive SD were elicited by switching to a medium containing 130 mM K+ for 20 min, each separated by 40 min of recovery (i.e. perfusion with normal ACSF). The brief negative shifts of the extracellular direct current (d.c.) potential, characteristic of SD elicitation, were recorded with the microdialysis electrode and a reference electrode placed under the scalp. Propagation of SD was examined using glass capillary electrodes inserted about 3 mm posterior to the microdialysis electrode. L-701,324 (5 or 10 mg kg-1) or its vehicle were administered i.v. 10 min after the end of the second K(+)-stimulus. The effects of L-701,324 were compared to those of dizocilpine (MK-801; 1 mg kg-1 i.v.), a NMDA-channel blocker known to potently block SD elicitation. 3. Potassium-induced SD initiation was inhibited by 10 mg kg-1 (but not by 5 mg kg-1) of L-701,324. Thirty minutes after administration of 10 mg kg-1 L-701,324, the cumulative area of SD peaks elicited during 20 min was 15.3 +/- 2.1 mV min, versus 23.2 +/- 1.1 mV min in animals which received only the drug vehicle (P < 0.02; n = 6). The delay between application of 130 mM K+ and occurrence of the first SD was also significantly increased. It was approximately doubled in animals treated with 10 mg kg-1 of L-701,324. 4. SD propagation was more sensitive than SD elicitation to L-701,324, as both 5 and 10 mg kg-1 produced an effective inhibition. Even at the lower dose of 5 mg kg-1, L-701,324 completely blocked the propagation of SD elicited 30 min after drug administration. This differential sensitivity of SD elicitation and propagation is not specific to L-701,324 since it was previously observed with other drugs. At doses effective against SD, L-701,324 did not produce any marked alterations of the electroencephalogram. 5. L-701,324 (10 mg kg-1) and MK-801 (1 mg kg-1) had identical effects on the d.c. potential when administered during the recovery which followed the second K+ stimulus. Both drugs produced a positive shift of around 4.5 mV within 10 min of i.v. drug administration, indicating rapid drug penetration into the CNS. Paradoxically, L-701,324 (10 mg kg-1) was markedly less effective than MK-801 (1 mg kg-1) in blocking SD, since this dose of MK-801 was sufficient virtually to abolish SD initiation and completely block its propagation. The higher potency of MK-801 against SD may reflect its use-dependency, i.e. binding of MK-801 and channel blockade are enhanced when the NMDA-receptor ionophore is open. 6. Taken together, these data demonstrate that L-701,324 has an inhibitory effect on both SD initiation and propagation. This action may be beneficial in focal ischaemia, and possibly also against migraine, especially as this drug was shown to be active when administered orally.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851513      PMCID: PMC1909404          DOI: 10.1111/j.1476-5381.1996.tb15283.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

1.  Regional cerebral blood flow during spreading cortical depression in conscious rats.

Authors:  R B Duckrow
Journal:  J Cereb Blood Flow Metab       Date:  1991-01       Impact factor: 6.200

2.  Volatile anesthetics and NMDA receptors. Enflurane inhibition of glutamate-stimulated [3H]MK-801 binding and reversal by glycine.

Authors:  D C Martin; J E Abraham; M Plagenhoef; R S Aronstam
Journal:  Neurosci Lett       Date:  1991-10-28       Impact factor: 3.046

3.  Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: relationship with phencyclidine-like behavioral effects.

Authors:  W Koek; F C Colpaert
Journal:  J Pharmacol Exp Ther       Date:  1990-01       Impact factor: 4.030

4.  Glutamate release and spreading depression in the fascia dentata in response to microdialysis with high K+: role of glia.

Authors:  J C Szerb
Journal:  Brain Res       Date:  1991-03-01       Impact factor: 3.252

Review 5.  The behavioral pharmacology of NMDA receptor antagonists.

Authors:  J Willetts; R L Balster; J D Leander
Journal:  Trends Pharmacol Sci       Date:  1990-10       Impact factor: 14.819

6.  Anaesthetic suppression of transmitter actions in neocortex.

Authors:  E Puil; H el-Beheiry
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

7.  Systemic ketamine blocks cortical spreading depression but does not delay the onset of terminal anoxic depolarization in rats.

Authors:  J Hernándéz-Cáceres; R Macias-González; G Brozek; J Bures
Journal:  Brain Res       Date:  1987-12-29       Impact factor: 3.252

8.  Evidence for a role of the N-methyl-D-aspartate (NMDA) receptor in cortical spreading depression in the rat.

Authors:  R Marrannes; R Willems; E De Prins; A Wauquier
Journal:  Brain Res       Date:  1988-08-09       Impact factor: 3.252

9.  General anaesthetics inhibit the responses induced by glutamate receptor agonists in the mouse cortex.

Authors:  V Carlà; F Moroni
Journal:  Neurosci Lett       Date:  1992-10-26       Impact factor: 3.046

10.  The effect of glutamate receptor blockade on anoxic depolarization and cortical spreading depression.

Authors:  M Lauritzen; A J Hansen
Journal:  J Cereb Blood Flow Metab       Date:  1992-03       Impact factor: 6.200

View more
  10 in total

Review 1.  Chaos and commotion in the wake of cortical spreading depression and spreading depolarizations.

Authors:  Daniela Pietrobon; Michael A Moskowitz
Journal:  Nat Rev Neurosci       Date:  2014-06       Impact factor: 34.870

Review 2.  Migraine genetics: an update.

Authors:  J Haan; E E Kors; Kaate R J Vanmolkot; Arn M J M van den Maagdenberg; Rune R Frants; M D Ferrari
Journal:  Curr Pain Headache Rep       Date:  2005-06

3.  Systematic review of the pharmacological agents that have been tested against spreading depolarizations.

Authors:  Anna Klass; Renan Sánchez-Porras; Edgar Santos
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-20       Impact factor: 6.200

4.  Glutamate release through volume-activated channels during spreading depression.

Authors:  T A Basarsky; D Feighan; B A MacVicar
Journal:  J Neurosci       Date:  1999-08-01       Impact factor: 6.167

Review 5.  Glutamate receptor antagonists in the management of migraine.

Authors:  Kayi Chan; Antoinette MaassenVanDenBrink
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

6.  Glycine and D: -serine, but not D: -cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801.

Authors:  Nobuhisa Kanahara; Eiji Shimizu; Shintaro Ohgake; Yuko Fujita; Mami Kohno; Tasuku Hashimoto; Daisuke Matsuzawa; Yukihiko Shirayama; Kenji Hashimoto; Masaomi Iyo
Journal:  Psychopharmacology (Berl)       Date:  2008-04-24       Impact factor: 4.530

7.  The impact of anesthetics and hyperoxia on cortical spreading depression.

Authors:  Chiho Kudo; Ala Nozari; Michael A Moskowitz; Cenk Ayata
Journal:  Exp Neurol       Date:  2008-04-11       Impact factor: 5.330

Review 8.  Cortical spreading depression: its role in migraine pathogenesis and possible therapeutic intervention strategies.

Authors:  Andrew A Parsons
Journal:  Curr Pain Headache Rep       Date:  2004-10

9.  Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study.

Authors:  James Galea; Kayode Ogungbenro; Sharon Hulme; Andrew Greenhalgh; Leon Aarons; Sylvia Scarth; Peter Hutchinson; Samantha Grainger; Andrew King; Stephen J Hopkins; Nancy Rothwell; Pippa Tyrrell
Journal:  J Cereb Blood Flow Metab       Date:  2010-07-14       Impact factor: 6.200

Review 10.  Cortical spreading depression as a target for anti-migraine agents.

Authors:  Cinzia Costa; Alessandro Tozzi; Innocenzo Rainero; Letizia Maria Cupini; Paolo Calabresi; Cenk Ayata; Paola Sarchielli
Journal:  J Headache Pain       Date:  2013-07-23       Impact factor: 7.277

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.